Final Ingenox cell diagram

AT101 is a small molecule with inhibitory activity against protein arginine methyltransferase 5 (PRMT5), developed through our in-house drug discovery capabilities. It prevents PRMT5 from symmetrically di-methylating arginine residues. The asset is undergoing IND-enabling studies with the aim of enrolling patients into a Phase I study at the earliest possible time.

Cold Tumours Toolkit MOA simplified (10 Feb 2023)-01

JASON Study on Immunologically Cold Cancers

This is a study that will investigate the safety and dosage of AT101. We have identified a group of biomarkers that correlate strongly with PRMT5-driven tumor response. AT101 also shows a differentiated profile when compared to competitor compounds, which could translate to a different risk-benefit ratio in the clinic.